Repotrectinib

본문 바로가기


Home > Product > Repotrectinib
Selling leads
Repotrectinib
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Lopsitinib (TPX-0005) is a fourth-generation ALK inhibitor developed by TPTherapeutics, founded by Dr. Cui Jingrong. It is a broad-spectrum ALK, ROS1 and TRK inhibitor, mainly targeting multiple acquired mutations. Including mutations such as ALKG1202R, ROS1G2032R and TRKAG595R. On June 28, 2017, TPTherapeutics announced that the FDA had granted orphan drug designation to its investigational clinical new drug compound PTX-0005 for NSCLC patients carrying ALK, ROS1 or NTRK oncogene rearrangements. Ptx-0005 is currently in the phase 1/2, open-label, multicenter clinical trial stage to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity in the patient population with advanced solid tumors with ALK, ROS1 or NTRK1-3 rearrangement mutations


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top